| |
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now.
|
|
Today's Big NewsNov 29, 2022 |
| By Nick Paul Taylor Bristol Myers Squibb is breaking off its collaboration and license agreement with uniQure, calling time on a pact that was intended to deliver gene therapies against multiple cardiovascular disease targets. |
|
|
|
By Nick Paul Taylor AstraZeneca is stepping up its pitch for a slice of the cell therapy space, paying $200 million upfront for a solid tumor player that recently hustled an autologous, fully individualized, multispecific prospect into the clinic. |
By Gabrielle Masson While other biotechs are culling staff and programs to stay afloat, BigHat Biosciences has remained dry under its ever-expanding umbrella, this time inking a multiproject deal with Merck & Co. while growing its team 30% since the summer. |
Sponsored by Slope Slope is revolutionizing the different levels of clinical trials through an all-in-one collaborative tool. Learn how Slope’s eClinical Supply Chain Management platform provides robust technology to the clinical trial space, covering all areas of supply management without losing sight of the chain of custody. |
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now.
|
|
By Gabrielle Masson In efforts to dominate radiopharmaceutical R&D, Full-Life Technologies is set to acquire New Jersey biotech Focus-X Therapeutics for a price tag that could max out at $245 million. |
Sponsored by Unlearn As leaders of clinical drug development, we owe it to trial patients to continuously innovate randomized control trial (RCT) designs that help to assuage fears of placebo by reducing the number of patients required to be enrolled in a control group — and to run faster trials that get answers sooner. |
By Max Bayer Hansa Biopharma says new phase 2 data of the company's one-trick-pony transplant treatment found that it beat standard of care in treating antibody-mediated resistance following a kidney transplant. The company is also testing the med prior to treatment of a couple of budding gene therapies. |
Sponsored by Ocugen Nuclear hormone receptors are master regulators of multiple molecular pathways. When used as a modifier gene therapy they could reverse the pathological phenotypes of multiple inherited retinal dystrophies (IRDs). |
By Helen Floersh An mRNA vaccine targeting 20 different subtypes of the flu protected mice and ferrets from severe disease and death, opening a door to a universal flu vaccine. |
By Kevin Dunleavy A week after GSK sidelined its multiple myeloma drug Blenrep, following a confirmatory trial failure, Roche has done the same for a key indication of its blockbuster cancer drug Tecentriq. Following consultation with the FDA, Roche has withdrawn Tecentriq's use as a first-line treatment for a form of advanced bladder cancer. The move is another in a growing list of accelerated approvals that have been overturned. |
By Joseph Keenan Spanish pharma Almirall has signed on to participate in a patient-driven project to collect and reutilize clinical trial participant data for further research or in healthcare practice. |
By Helen Floersh Scientists have learned how cancer cells use a key molecule to fend themselves against chemotherapy—and have come up with a way to target it directly. |
By Fraiser Kansteiner In a bout of M&A whiplash, Bloomberg News broke the story that Chinese conglomerate Fosun was working with an adviser to weigh buyer interest in its controlling stake in Gland Pharma. But Gland, which charted its own buyout Tuesday morning, quickly surfaced on the Indian stock market to respond. |
By Andrea Park The latest version of Philips’ diagnostic imaging platform adds a handful of artificial-intelligence-powered programs that aim to hugely cut down on the time and effort it takes to turn a preliminary scan into a solid diagnosis. |
By Frank Diamond Vaccinated individuals still stand a much greater chance of surviving COVID-19 than unvaccinated individuals. Still, scientists keep a wary eye on troublesome trends. |
Fierce podcastsDon't miss an episode |
| | This week The Top Line discusses pharma's ad spending for 2021, an intriguing executive move at Novartis and more. |
|
|---|
|
|
|
Thursday, December 8, 2022 | 11am ET/8am PT Frontage Laboratories will dive into their Quantitative Whole Body Autoradiography (QWBA) services. They will look at Radiation Dosimetry reports that support human Absorption, Metabolism, and Excretion (hAME) studies at one of their clinical sites. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
